Generate Biomedicines Q2 net loss widens to $67.3 million; revenue falls to $6.3 million
Generate Biomedicines reported results for the quarter ended June 30, 2026, with collaboration revenue of $6.3 million, down from $10.1 million a year earlier, and a net loss of $67.3 million, up from $56.7 million. Cash, cash equivalents, and marketable securities were $457.4 million, down from $516.6 million at March 31, 2026, and the company says it expects to need additional capital to support long-term operations, which matters to shareholders because it signals future funding needs.
Key points
- Collaboration revenue was $6.3 million for the quarter, compared with $10.1 million for the same period in 2025.
- Net loss was $67.3 million, compared with $56.7 million, and research and development expenses rose to $64.3 million from $59.7 million.
- Cash and marketable securities totaled $457.4 million at June 30, 2026, which the company says can fund its current operating plan into the first half of 2028.
The filing
Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.